Join Today!

Become a member and connect with:

An Active Online Community
Articles and Advice on SCD
Help Understanding Clinical Trials

researchers

John F. Tisdale, MD

Researcher
Senior Investigator
Molecular and Clinical Hematology Section
NIH
National Heart, Lung, and Blood Institute
Building 10, Room 9N112
Bethesda, Maryland, United States

John F. Tisdale, MD graduated from the College of Charleston in South Carolina with a B.A. in chemistry in 1986. He then earned his M.D. from the Medical University of South Carolina in 1990. Dr. Tisdale is currently working on multiple strategies both in the laboratory and in the clinic to cure sickle cell disease by repairing or replacing the precursor bone marrow cells that give rise to sickled red blood cells. Dr. Tisdale has an active research program in trying to characterize tolerance and create conditions in which patients will more easily tolerate donor cells and tissues without the need for destroying the immune system or perpetual use of immunosuppressant drugs. Dr. Tisdale and his colleagues also have an ongoing research agenda to find a gene therapy strategy for SCD. This project is in an earlier phase of development, although accrual to a protocol testing this approach has begun.

Representative Publications:

Allogeneic hematopoietic stem-cell transplantation for sickle cell disease

At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT

Measurements of red cell deformability and hydration reflect HbF and HbA2 in blood from patients with sickle cell anemia

Bone Marrow as a Hematopoietic Stem Cell Source for Gene Therapy in Sickle Cell Disease: Evidence from Rhesus and SCD Patients

Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia

Kinetic assay shows that increasing red cell volume could be a treatment for sickle cell disease

view full profile